Clinically validated oral intervention for ad: 22% a\beta reduction & rwe-proven safety (n=407)

Listing details

[What it is & Why it matters] We offer a clinically validated, natural product-derived oral intervention for Alzheimer's Disease (AD) and MCI. Designed for a "Selection-Prevention" model, this asset addresses the industry's critical unmet need for a safe, early-stage disease-modifying therapy that integrates seamlessly with blood-based biomarker diagnostics.

[How it works] The proprietary formulation targets multiple neuropathological pathways. Preclinical studies, published in the Journal of Alzheimer's Disease (2021), demonstrate its mechanism of action: reducing both Amyloid-beta (A\beta) and Tau proteins while improving cognitive function through AMPK phosphorylation and BACE1 inhibition.

[Proof to date] Our asset is uniquely backed by massive Real-World Evidence (RWE) and precise biomarker data: Unmatched Safety: Administered to 1,000+ patients over 5 years with zero serious adverse events or liver toxicity.

Clinical Efficacy: A longitudinal analysis of 407 patients (treated 6+ months) demonstrated a 77.6% clinical response rate (CGI-I). Biomarker Validation: 100% of monitored patients showed reduced plasma A\beta. We achieved an average 20% reduction, with high-risk ApoE4/4 carriers showing a 22% reduction within 6 months. This trajectory significantly outperforms the NCAA (Normal Aging) cohort.

[Next steps] A 5-patient case study is currently under SCI journal review, and we are actively conducting a 15-patient A\beta comparative study. We are now launching a 30-subject trial focused on the global A/T/N (Amyloid, Tau, NfL) triple-marker framework.

We seek strategic partners for Licensing, Co-development, or Sponsored Research to establish a new "Amyloid & Tau Dual Care" standard in the global Pharmaceutical and Medical Food markets.